u.s.
.
.
.
joe sanjo
.
1
.
.
following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv).
.
it shows that the longest waits for cancer treatment have soared since 2010.
.